Palo Alto, CA-based Affymax (NASDAQ: [[ticker:AFFY]]) and its partner, Japan-based Takeda Pharmaceuticals, said today that the FDA has agreed to review their application to market a new anemia drug in the U.S. If the FDA agrees to clear peginesitide (formerly known as Hematide) for sale in the U.S., it would be the first once-monthly anemia drug for patients with kidney dialysis, and would compete with products from Amgen.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
